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A b s t r a c t  The antagonist effects of clocinnamox were 
evaluated against opioid agonists, acting at It, ~: and 0-re- 
ceptors, in rhesus monkeys (n=3-4) responding under a 
fixed-ratio 30 (FR 30) schedule for food delivery. Clo- 
cinnamox (0.032-0.1 mg/kg) dose-dependently antago- 
nized fentanyl (0.001-0.32 mg/kg) after either a 3-h or 
1-day pretreatment; there was substantial recovery of ag- 
onist potency by 1 week after clocinnamox. Etonitazene 
(0.0001-0.01 mg/kg) was also antagonized by clo- 
cinnamox (0.1 mg/kg), but to a lesser extent than fenta- 
nyl. The smaller extent of antagonism was not due to the 
appearance of non ~t-opioid response-decreasing effects 
of etonitazene, since the competitive antagonist quadazo- 
cine (0.1 mg/kg) shifted the etonitazene dose-effect 
curve in the presence of clocinnamox (0.1 mg/kg). Clo- 
cinnamox (0.1-0.32 mg/kg) did not antagonize the rate- 
suppressing effects of the 0-agonist BW373U86 (0.0.01- 
1.0 mg/kg) or the ~c-agonist U69,593 (0.001-0.032 
mg/kg), These results are consistent with previous in vi- 
vo and in vitro evidence that characterized clocinnamox 
as an insurmountable antagonist, with selectivity for ~t- 
over ~:- and g-receptors. 
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Introduction 
Irreversible opioid antagonists such as ~3-funaltrexamine 
([3-FNA) have been used as a way to study both the se- 
lectivity and the efficacy of different agonists in a variety 
of experimental conditions, in vivo (e.g., Zimmerman et 
al. 1987; Adams et al. 1990; Mjanger and Yaksh 1991). 
The cinnamoylmorphinone, clocinnamox, has recently 
been characterized in tests of antinociception in mice 
and monkeys (Comer et al. 1992; Burke et al. 1994; Zer- 
nig et al. 1994), and was described as an irreversible opi- 
oid antagonist with relative selectivity for g- over ~¢- and 
0-opioid receptors. An advantage of clocinnamox rela- 
tive to [3-FNA in behavioral studies is that the former 
does not have an initial, probably ~:-receptor mediated 
(e.g., Ward et al. 1982) agonist effect which limits be- 
havioral testing soon (i.e., <24 h) after [3-FNA adminis- 
tration. Burke et al. (1994) reported a correspondence 
between the antagonist effects of clocinnamox against 
the antinociceptive effects of morphine in mice and an 
observed decrease in the number of g-receptor binding 
sites in mouse brain. Thus, clocinnamox (IR 3.2 mg/kg) 
produced an almost total suppression in [3H]DAMGO 
([D-Ala 2, N-Me-Phe 4, glycolSl-enkephalin) binding sites 
in mouse brain, peaking 1 h after administration, and the 
number of sites substantially recovered by 8 days after 
administration. At this dose, clocinnamox caused a large 
right and downward shift in the morphine dose-effect 
curve in thermal antinociception, and clocinnamox did 
not have an antinociceptive effect by itself. The time 
course of the suppression of morphine's antinociceptive 
effects mirrored well the decrease in [3H]DAMGO bind- 
ing sites (Burke et al. 1994). More recent in vitro and ex 
vivo experiments in mice confirmed that clocinnamox 
exhibited wash-resistant binding at g-, but not ~;- or 0-, 
receptors, thus supporting the in vivo selectivity of its 
antagonist effects (Zernig et al. 1994, 1995; Broadbear et 
al., manuscript in preparation). 
In the present studies, we examined whether clo- 
cinnamox presented an opioid antagonist profile in a 
non-antinociceptive behavioral assay in rhesus monkeys, 
i.e., suppression of schedule-controlled fo0d-reinforced 
responding. This procedure is a simple means to study 
the pharmacology of bt- (e.g., etonitazene and fentanyl), 
~:- (e.g., U69,593), and 0 -  (e.g., BW373U86) opioid ag- 
onists in vivo in rhesus monkeys (Negus et al. 1993, 
1994), and is especially helpful in evaluating clo- 
cinnamox's  bt- over 0-selectivity, given that the only non- 
peptide O-agonist characterized to date, BW373U86, is 
inactive as a thermal analgesic in rhesus monkeys, but 
does suppress food-reinforced responding through a 0- 
receptor mechanism (see Negus et al. 1994; Butelman et 
al. 1995b). 
Materials and methods 
Subjects 
The subjects were seven adult male and female rhesus monkeys, 
weighing between 7 and 12 kg during the course of the study. 
They were housed individually with free access to water and con- 
trolled amounts of Purina monkey chow, supplemented by fresh 
fruit at least twice per week. 
Apparatus 
The apparatus and other experimental details have been described 
previously (Negus et al. 1993). During experimental sessions, one 
of the subjects was placed in a standard primate restraint chair, 
which was then placed inside a sound-attenuating behavioral cubi- 
cle equipped with a panel containing two levers and stimulus 
lights above the levers. The remaining subjects were tested in their 
home cages, which were also equipped with a panel containing 
two levers and stimulus lights. Experimental panels had a food re- 
ceptacle mounted centrally, just below the panels themselves. Ex- 
ternally mounted pellet dispensers delivered 300 mg banana fla- 
vored pellets (RJ. Noyes Co., Lancaster, N.H.). All programming 
and data collection were carried out with IBM PCjr computers. 
Experimental sessions 
Sessions were carried out 5-6 days/week; during training days, 
sessions were composed of five consecutive 15-min cycles. Each 
cycle was composed of an initial 10-min timeout period during 
which responses on any lever had no programmed consequence. 
This was followed by a 5-rain response period, during which 
stimuls lights were illuminated and 30 lever presses resulted in 
pellet delivery (FR30). Subjects could obtain a maximum of ten 
pellets/cycle. 
Test sessions 
During test sessions, agonist doses were administered at the begin- 
ning of each cycle, using a cumulative dosing procedure, increas- 
ing by 1/2 log unit steps. Dosing continued until responding was 
eliminated in each subject, or after the appearance of untoward ef- 
fects, such as preconvulsant behavior in the presence of 
BW373U86. Dose-effect curves were determined for etonitazene, 
fentanyl, BW373U86 and U69,593. These dose-effect curves were 
redetermined 3 h (fentanyl only), 1 day and 1-2 weeks after pre- 
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treatment with single clocinnamox doses (0.032-0.32 mg/kg, 
n=3-4). In another experiment, the etonitazene dose-effect curve 
was also redetermined 30 rain after pretreatment with quadazocine 
(0.1 mg/kg), either alone or 1 day after clocinnamox pretreatment 
(0.1 mg/kg). 
Data analysis 
Rates of responding (responses per second) were collected for 
each subject individually, and were expressed as a percentage of 
the mean control rate, determined fiom the previous training day. 
Individual EDs0 values were calculated by linear regression from 
points above and below the 50% level. Mean EDs0 and 95% confi- 
dence limits (95% CL) were calculated after log transformation of 
individual EDs0 values. 
Drugs 
Quadazocine methanesulfonate (Sterling Winthrop, Rensselaer, 
N.Y.), fentanyl hydrochloride (NIDA, Rockville, Md.), etonitazene 
hydrochloride (NIDA, Rockville, Md.), BW373U86 [(+)-4-(R*) 
((2S*5R*)-4-allyl-2,5,-dimethyl- 1-piperazinyl)-3-hydroxybenzyl)- 
N,N-diethylbenzamide dihydrochloride] (Burroughs Wellcome, 
Reasearch Triangle Park, N.C.), U69,593 (Upjohn Co., Kalama- 
zoo, Mich.) and clocinnamox mesylate (Dr. John Lewis, Bristol 
University, UK) were all dissolved in sterile water and injected SC 
in the thigh or the back, typically at volumes of 0.1 ml/kg body 
weight. All drug doses were expressed as salt weights. 
Results 
Control performance 
Subjects were easily trained on the schedule, and typical- 
ly yielded stable rates of  responding for all the cycles in 
training sessions. Control rates of responding ranged 
from two to four responses/s for all the monkeys studied. 
Agonist dose-effect curves 
All of the opioid agonists suppressed dose-dependently 
and completely the rates of  food-reinforced responding 
in all the monkeys tested. At doses that completely sup- 
pressed responding, no obvious signs of  intoxication 
were present. The EDs0 values for suppression of re- 
sponding by each of the agonists are presented in Table 
1. 
Antagonist effects of  clocinnamox 
Clocinnamox alone did not affect rates of responding on 
the day it was administered (not shown). When clo- 
cinnamox (0.032 mg/kg) was administered before fenta- 
nyl, a rightward shift in the fentanyl dose-effect curve, 
approximately 1 log unit in magnitude, was observed 
24 h after pretreatment (ED50=0.019 mg/kg). The fenta- 
nyl dose-effect curve had returned to baseline by 1 week 
after clocinnamox (0.032 mg/kg, Fig. 1). When a higher 
clocinnamox dose (0.1 mg/kg) was administered before 
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Table 1 EDs0 values for opioid 
agonists alone and 1 day after 
pretreatment with clocinnamox 
(0.1 mg/kg) 
Agonist alone 0.1 mg/kg Clocinnamox D.R. b 
EDs0a (+95% CL) ED50 (+95% CL) 
Etonitazene 0.0005 0.0004-0.0006 0.003 0.0007-0.01 * 6 
Fentanyl 0.002 0.001-0.006 0.06 0.01-0.3" 30 
BW373U86 0.09 0.009-0.8 0.1 0.003-3.6 1.1 
U-69,593 0.004 0.001-0.01 0.009 0.003-0.03 2.3 
a EDs0: dose required to reduce response rates to 50% of control 
b D.R.: dose ratio, i.e. [EDs0 clocinnamox/ED50 agonist alone] 
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Fig. 1 Time course of the antagonist effects of clocinnamox 
(CLO, 0.032 and 0.1 mg/kg, upper and lower panels, respectively) 
pretreatment against fentanyl. Upper panel: fentanyl dose-effect 
curves were redetermined 1 and 7 days (D) after a single clo- 
cinnamox (CLO, 0.032 mg/kg) pretreatment. Lower panel: fenta- 
nyl dose-effect curves were redetermined 3 h (3 I4), and 1, 7, and 
14 days after clocinnamox (0.1 mg/kg. Data in the lower panel 
were obtained in two separate experiments, one in which the 3-h 
time point alone was tested, another in which the remaining time 
points were tested. Abscissae: dose of fentanyl (mg/kg); ordinates: 
rate of responding expressed as a percent of control, _+SEM 
fentanyl, a larger shift of the fentanyl dose-effect curve, 
approximately 1.5 log units in magnitude, was observed 
both 3 and 24 h later (the two dose-effect curves were 
carried out after two separate clocinnamox administra- 
tions; see Table 1). The fentanyl dose-effect curve also 
returned to approximate baseline levels within 1 week of 
0.1 clocinnamox pretreatment (Fig. 1). 
Clocinnamox (0.1 mg/kg) also shifted the etonitazene 
dose-effect curve 1 day after administration (see Fig. 2 
and Table 1). The magnitude of the shift was 0.75 log 
units, approximately, and complete recovery was ob- 
Fig. 2 Upper panel: time course of the antagonist effects of clo- 
cinnamox (0.1 mg/kg) against etonitazene. Lower panel: effect of 
quadazocine (QUAD, 0.1 mg/kg) pretreatment, 30 rain before eto- 
nitazene, tested in the presence or the absence of clocinnamox 
(0.1 mg/kg). Etonitazene baseline (BL) and 0.1 mg/kg clo- 
cinnamox pretreatment are repeated in the two panels. All other 
details as in Fig. 1 
served by 1 week after clocinuamox. In a separate exper- 
iment, the competitive opioid antagonist quadazocine 
(0.1 mg/kg) was administered 30 min before etonitazene, 
either 24 h after clocinnamox (0.1 mg/kg), or in its ab- 
sence. Quadazocine (0.1 mg&g) alone caused a signifi- 
cant rightward shift, approximately 1.5 log units in mag- 
nitude, in the etonitazene dose-effect curve (EDs0= 
0.01 mg/kg; Fig. 2). In the presence of clocinnamox, 
quadazocine (0.1 mg/kg) caused a similar shift, also ap- 
proximately 1.5 log units in magnitude, of  the etonitaz- 
erie dose-effect curve (EDs0=0.14 mg/kg; Fig. 2). (0.1 
mg/kg) did not antagonize the rate-decreasing effect of  
BW373U86, and only caused a small and non-significant 
shift in the U69,593 dose-effect curve (Table 1). A larger 
clocinnamox pretreatment dose (0.32 mg/kg) was also 
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studied in combination with U-69,593 and BW373U86. 
This clocinnamox dose caused no further shift in the 
rate-decreasing effects of U69,593 or BW373U86, 24 h 
after administration (data not shown). 
Discussion 
Clocinnamox has previously been described as an irre- 
versible opioid antagonist in tests of antinociception in 
mice and rhesus monkeys (Comer et al. 1992; Burke et 
al. 1994; Zernig et al. 1994). The present findings extend 
the characterization of its antagonist effects in a different 
assay, suppression of operant, food-reinforced respond- 
ing, which has been previously used to characterize g-, 
1<- and 0-opioid agonists and antagonists (e.g., Negus et 
al. 1993; 1994). In the present study, clocinnamox 
(0.032-0.32 mg/kg), in common with other opioid antag- 
onists (see Negus et al. 1993, 1994), did not cause by it- 
self a suppression in operant responding, but dose-de- 
pendently and robustly antagonized the effects of the B- 
agonists etonitazene and fentanyl. The peak antagonist 
actions of clocinnamox (0.1 mg/kg) against etonitazene 
and fentanyl were observed up to 1 day after administra- 
tion, and there was substantial or complete recovery by 1 
week. A similar time course was observed with thermal 
antinociception in rhesus monkeys, in which clo- 
cinnamox (0.1 mg/kg) antagonism of alfentanil's actions 
had substantially diminished by 1 week after pretreat- 
ment (Zernig et al. 1994). The g-antagonist effects of 
clocinnamox (0.1 mg/kg) were surmountable in the pres- 
ent test of response rate suppression, but insurmountable 
in a test of antinociception in rhesus monkeys (i.e., 50°C 
warm water tail withdrawal; Zernig et al. 1994). This dif- 
ference could suggest the presence of a larger receptor 
reserve for response rate suppression than for anti- 
nociception, or that a lower level of receptor occupancy 
is required for (:he former endpoint than for the latter. 
Consistent with this, the opioid agonist doses required 
for response rate suppression tend to be smaller than 
those required for antinociception (e.g., present study; 
Walker et al. 1993; France et al. 1994). 
Conversely, clocinnamox did not significantly antago- 
nize the rate-decreasing effects of a 1<- (U-69,593) and a 
0- (BW373U86) agonist, even at the highest dose that 
could be administered due to clocinnamox solubility 
(0.32 mg/kg). It has previously been shown that the ago- 
nist effects of U-69,593 and BW373U86 in this proce- 
dure were mediated by ~:- and 0-receptors, respectively, 
as determined in quantitative studies with the competi- 
tive antagonists, quadazocine and naltrindole (Negus et 
al. 1993, 1994). Thus clocinnamox's lack of antagonism 
of these two agonists in the procedure, shows that clo- 
cinnamox exhibits considerable selectivity for It- over 1<- 
and 0-receptors in this procedure. The selectivity of clo- 
cinnamox for B- over ~:-receptors in monkeys has previ- 
ously been reported in the warm water tail withdrawal 
test of antinociception in rhesus monkeys (Zernig et al. 
1994; Butelman et al. 1995a)). The selectivity of clo- 
cinnamox for ~t- over 0-receptors, however, could not be 
evaluated in the same procedure, because the prototypic 
non-peptide 0-agonist, BW373U86 is inactive in the 
warm water tail withdawal assay (Negus et al. 1994). 
Thus the present data are, to our knowledge, the first to 
indicate clocinnamox's B- versus 0-selectivity in a pri- 
mate species. In binding studies, clocinnamox displayed 
approximately 30-fold ~t- over ~c-selectivity, and 6-fold 
~t- over 0-selectivity. Furthermore, only binding at g-, 
but not I<- or 0-, opioid sites was highly resistant to re- 
peated washing (Zernig et al. 1995). This profile results 
in clocinnamox having considerable selectivity in vivo 
for ~t-receptors. 
An interesting aspect of the g-antagonist effects of 
clocinnamox (0.1 mg/kg, 24 h after administration) in 
the present studies is that it apparently produced a larger 
shift of fentanyl's dose-effect curve compared to etoni- 
tazene's dose-effect curve. It has previously been sug- 
gested that varying agonist efficacy results in differential 
sensitivity to irreversible antagonism. For example, the 
g-selective irreversible antagonist, ~3-FNA, produced 
larger shifts in the antinociceptive dose-effect curves of 
agonists thought to have low efficacy, relative to agonists 
thought to have high efficacy. This trend was observed in 
rodents in a variety of assays (tail flick, hot plate, ab- 
dominal constriction) following either central or system- 
ic administration (Zimmerman et al. 1987; Adams et al. 
1990; Mjanger and Yaksh 1991). The present data there- 
fore suggest that fentanyl has lower efficacy than etoni- 
tazene in this procedure. Etonitazene has previously been 
described as having higher efficacy than the fentanyl 
congener, alfentanil, in thermal antinociception in rhesus 
monkeys (Walker et al. 1995). Relevant to this issue, 
quadazocine (0.1 mg/kg) pretreatment caused a further 
shift in the etonitazene dose-effect curve in the presence 
of clocinnamox, of similar magnitude than observed in 
the absence of clocinnamox. This quadazocine pretreat- 
ment dose (0.1 mg/kg) would not antagonize the effects 
of 0- or ~:-agonists in this procedure (see Negus et al. 
1994). Therefore, the extent of the clocinnamox-induced 
shift in etonitazene's dose-effect curve was not limited 
by the appearance of non B-opioid receptor-mediated ef- 
fects. An alternative explanation for clocinnamox's dif- 
ferential shift of the etonitazene and fentanyl dose-effect 
curves is the possibility that these compounds had differ- 
ential affinity for putative g-receptor subtypes (e.g., Pas- 
ternak 1993). This explanation cannot be evaluated at 
present, due to a lack of information on B-subtype phar- 
macology in primates. 
The present data show that clocinnamox acts as a rel- 
atively long-lasting, B-selective antagonist in rhesus 
monkeys in a non-antinociceptive endpoint, and that it is 
devoid of an initial agonist effect. These findings extend 
previous data obtained in the procedure with the compet- 
itive antagonists quadazocine and naltrindole (Negus et 
al. 1993, 1994). Thus clocinnamox, which shows insur- 
mountable antagonist effects in tests of antinociception 
in primates (Zernig et al. 1993), can be studied in this 
simple operant procedure, which is sensitive to a variety 
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of  opio ids  that may  be inact ive in other  behaviora l  end- 
points ,  inc luding  tests of  ant inocicept ion.  
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